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Abstract: Elderly patients (age $65 years) with hypertension are at high risk for vascular 
complications, especially when diabetes is present. Antihypertensive drugs that inhibit the 
renin-angiotensin system have been shown to be effective for controlling blood pressure in 
adult and elderly patients. Importantly, renin-angiotensin system inhibitors were shown to have 
benefits beyond their classic cardioprotective and vasculoprotective effects, including reduc-
ing the risk of new-onset diabetes and associated cardiovascular effects. The discovery that the 
renin-angiotensin system inhibitor and angiotensin II type 1 (AT1) receptor blocker (ARB), 
telmisartan, can selectively activate the peroxisome proliferator-activated receptor-γ (PPARγ, 
an established antidiabetic drug target) provides the unique opportunity to prevent and treat 
cardiovascular complications in high-risk elderly patients with hypertension and new-onset 
diabetes. Two large clinical trials, ONTARGET (Ongoing Telmisartan Alone in combination 
with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt 
Study in ACE-I iNtolerant subjects with cardiovascular disease) have assessed the cardiopro-
tective and antidiabetic effects of telmisartan. The collective data suggest that telmisartan is 
a promising drug for controlling hypertension and reducing vascular risk in high-risk elderly 
patients with new-onset diabetes.
Keywords: elderly, hypertension, telmisartan, angiotensin II type 1 receptor blocker, peroxi-
some proliferator-activated receptor-γ, diabetes, vascular risk
Introduction
The worldwide increase in the elderly population (age $65 years) is associated with 
concurrent increases in prevalence of systemic hypertension and morbidity and mortal-
ity from vascular complications of hypertensive disease.1 The elderly population with 
hypertension and new-onset diabetes is at especially high risk for vascular compli-
cations.1 Antihypertensive drugs that inhibit the renin-angiotensin system have been 
shown to control blood pressure effectively in adult and elderly patients.2–8 Importantly, 
renin-angiotensin system inhibitors have been shown to have benefits beyond their 
classic cardioprotective and vasculoprotective effects, including reducing the risk of 
new-onset diabetes.2,3 Evidence from randomized clinical trials suggests that this may 
be a class effect of the renin-angiotensin system inhibitors. Recently, the ability of the 
renin-angiotensin system inhibitor and angiotensin II type 1 (AT1) receptor blocker 
(ARB), telmisartan, to activate the peroxisome proliferator-activated receptor-γ (PPARγ) 
selectively, an established antidiabetic drug target, provides the unique opportunity to 
prevent and treat cardiovascular complications in high-risk elderly patients with hyper-
tension and new-onset diabetes.9–13 Telmisartan has been shown to have beneficial effects Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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on hypertension, as well as lipid and glucose metabolism,9–13 
without the side effects of fluid retention, weight gain, and 
heart failure associated with thiazolidinedione ligands of 
PPARγ.14 Combined renin-angiotensin system inhibition and 
selective PPARγ modulation with telmisartan could therefore 
provide additional protection in elderly hypertensive patients 
with new-onset diabetes compared with renin-angiotensin 
system inhibition alone.
Recently, two large randomized clinical trials, ONTAR-
GET (Ongoing Telmisartan Alone in combination with 
Ramipril Global Endpoint Trial)15,16 and TRANSCEND 
(Telmisartan Randomized AssessmeNt Study in ACE-I iNtol-
erant subjects with cardiovascular disease)17,18 have assessed 
the cardioprotective and antidiabetic effects of telmisartan 
and the angiotensin converting enzyme (ACE) inhibitor 
ramipril in high-risk, mostly elderly patients.15–18 A few 
small studies evaluated the efficacy of telmisartan in elderly 
patients with primary hypertension alone,19 or associated 
with cerebral infarction,20 type 2 diabetes,21 and metabolic 
syndrome.22 This article reviews the clinical effectiveness of 
telmisartan alone or in combination therapy for controlling 
blood pressure and vascular risk in the elderly.
Who are the elderly people?
Because aging is a continuous biologic process, there is no 
biomarker that separates elderly from nonelderly patients. 
Evidence indicates that aging leads to multiple changes 
(Tables 1 and 2) that impact cardiovascular physiology and 
pathophysiology.23 The chronologic age of 65 years became 
the definition of elderly by default.24 Data from population 
studies and randomized clinical trials since the 1950s sug-
gest that this arbitrary cutoff of 65 has clinical relevance.1 
Thus, the prevalence of hypertension increases progressively 
with age, but the vascular complications associated with 
hypertension increase sharply after age 65 years, including 
stroke, myocardial infarction, heart failure, and renal failure.1 
The same is true for comorbidities such as type 2 diabetes, 
metabolic syndrome, and obesity, which appear to aggravate 
the vascular complications.1 Importantly, the negative impact 
of vascular complications increases with aging.1 Thus, the 
risk of dying of myocardial infarction increases progressively 
across three segments, ie, the younger elderly aged 65–74 
years, the older elderly aged 75–84 years, and the very elderly 
aged .85 years.25
The elderly and cardiovascular risk
Ten points relating to the interaction between aging and 
cardiovascular risk factors deserve mention. First, evidence 
indicates that risk factors influence cardiovascular disease 
progression and aging is an independent predictor of mortal-
ity and morbidity.1 Second, interactions between risk factors 
(ie, genetic factors, stress, diet, cigarette smoking, sedentary 
lifestyle, dyslipidemia, hypertension, obesity, diabetes, and 
metabolic syndrome) and the cardiovascular system lead 
to vascular disease (including hypertension) and its com-
plications, including coronary artery disease, myocardial 
infarction, carotid artery disease, stroke, left ventricular 
dysfunction, heart failure, peripheral artery disease, and 
renal failure.1 Third, cardiovascular risk factors (including 
hypertension) contribute to vascular disease progression and 
end organ pathologies.1 Fourth, besides hypertension, comor-
bidities that are prevalent in the elderly (including coronary 
artery disease, obesity, and type 2 diabetes) increase risk and 
accelerate progression toward stroke, myocardial   infarction, 
Table 1 Biologic changes in cardiovascular aging
• ↓ Myocyte number, ↑ myocyte size
• ↓ Leucocyte telomere length
• Altered neurohumoral pathways
• Altered contractile pathways
• Altered stress response pathways
• Altered responses to injury
• Altered repair responses
• Altered cardiac and arterial responses
• Altered genes
• Altered cellular and mitochondrial function
• Altered immune responses
• Altered metabolism and metabolic reserve
Notes: ↑, increase; ↓, decrease.
Table 2 Physiologic changes and pathophysiologic hallmarks of 
cardiovascular aging
• ↑ Systolic blood pressure and pulse pressure
• Concentric ventricular remodeling, ↑ mass/volume ratio
• ↑ Extracellular matrix (fibrillar collagen)
• ↑ Advanced glycation end products
• ↑ Fibrosis and collagen cross-linking
• ↓ Diastolic function and relaxation
• vascular remodeling
• ↑ ventricular-arterial stiffening, altered coupling
• Atrial remodeling, ↑ atrial fibrillation
• ↓ Cardiac reserve
• Impaired response to stress
• Impaired healing
• ↑ Coronary heart disease and sequelae
• ↑ Peripheral artery disease and sequelae
• ↑ Cerebrovascular disease and sequelae
• ↑ Interaction with cardiovascular risk factors
• ↑ Comorbidities
Notes: ↑, increase; ↓, decreaseClinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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heart failure, renal failure, severe disability, and death.1 Fifth, 
aging increases risk, and cardiovascular disease is more 
severe and causes more deaths in elderly men and women. 
Sixth, the Framingham study found six main risk factors for 
stroke (age, systolic blood pressure, use of antihypertensive 
therapy, type 2 diabetes, cigarette smoking, and prior cardio-
vascular disease).26,27 Seventh, despite unclear associations 
between lipids and stroke,27 studies with lipid-modifying 
drugs indicate that dyslipidemia is an important risk factor 
for stroke.28 Eighth, the INTERHEART study, which ranked 
potentially modifiable risk factors for myocardial infarction 
in five age groups (,45, 46–55, 56–65, 66–70, .70 years), 
found that nine factors account for most of the risk of myo-
cardial infarction, including abnormal lipids, hypertension, 
diabetes, and abdominal obesity.29 Ninth, patients with 
evidence of vascular disease such as myocardial infarction, 
stroke, transient ischemic stroke, and peripheral vascular 
disease represent a high-risk group for major cardiovascular 
events and the risk is greater in the elderly.30,31 Tenth, the role 
of hypertension in cardiovascular disease and the ability of 
antihypertensive drugs to reduce risk are well established.32 
In older persons with isolated systolic hypertension, a his-
tory of diabetes is an important risk factor for lacunar stroke, 
whereas carotid bruit and age are important risk factors for 
atherosclerotic and embolic stroke.26
Demographics of hypertension  
in the elderly
In the US, hypertension defined as blood pressure 
$140/90 mmHg, affects at least 74.5 million of the adult 
population.1 Prevalence increases with age, with half to 
two-thirds of hypertensives being elderly and 75% aged .80 
years. There is a gender difference, with age-adjusted preva-
lence between 1999 and 2002 being 78% for elderly women 
and 64% for elderly men. The profile of hypertension is 
altered with aging and there is again a gender difference; 
systolic blood pressure increases, whereas diastolic blood 
pressure stays relatively constant between age 50–80 years, 
with the average diastolic blood pressure higher in men 
than women. Isolated systolic hypertension without a rise in 
diastolic blood pressure occurs in 8% of the population aged 
60 years and .25% in those aged .80 years.
Complications of hypertension increase with age.1 The 
prevalence of silent stroke also increases with aging, being 
22% in those aged 65–69 years, and 43% in those aged $85 
years. Prevalence of myocardial infarction and heart failure 
is highest in the elderly.1 Chronic conditions are also more 
common in the elderly, most prominent among these being 
heart disease and diabetes.1 Diabetes also increases with 
aging, with the largest increases projected for the oldest 
groups.1 More than 80% of all deaths from cardiovascular 
disease occur in the elderly, with approximately 60% in those 
aged .75 years.1 For 2010, the estimated total costs (indirect 
plus direct) in billions are $76.6 for hypertensive disease, 
$73.7 for stroke, and $39.2 for heart failure, respectively.1
Epidemiology of hypertension  
in the elderly
The pharmacologic treatment of hypertension has improved 
since the 1990s. However, hypertension in the elderly does 
not occur in isolation. Typically, other cardiovascular dis-
eases, comorbidities, and polypharmacy are common, making 
therapy more challenging. The profile of hypertension, as 
well as commonly associated cardiovascular diseases, such 
as coronary heart disease and heart failure, differ from that 
in nonelderly patients. Systolic hypertension is common and 
becomes a stronger predictor of cardiovascular events, espe-
cially in older women. Heart failure is also more prevalent and 
heart failure with preserved ejection fraction more common, 
especially in older women. Coronary artery disease is more 
common and more likely to involve multiple vessels and the 
main left artery. Myocardial infarction is more prevalent and 
is equally distributed in elderly men and women until the age 
of 80 years, after which it is more frequent in women. The risk 
of heart failure, severity of hypertension, and hypertension 
with antecedent myocardial infarction increase with aging.1 
Myocardial infarction usually results in dilative ventricular 
remodeling and systolic heart failure, also called heart failure 
with low ejection fraction.30 In contrast, hypertensive disease 
usually results in concentric remodeling and diastolic heart 
failure, also called heart failure with preserved ejection 
fraction.30 Nearly 50% of elderly patients have heart failure 
with low ejection fraction whereas approximately 50% of all 
heart failure patients have heart failure with preserved ejec-
tion fraction, and its prevalence is higher in the elderly.30 In a 
recent study of heart failure with preserved ejection fraction, 
all patients were very elderly, with a mean age of 87 years.33 
Whereas pharmacologic therapies for heart failure with low 
ejection fraction are available, therapies for heart failure with 
preserved ejection fraction are lacking.30 Because elevated 
blood pressure is the main cause, tight blood pressure control 
is important for prevention.
Diabetes is not only more prevalent in the elderly, but 
increases cardiovascular risk, and more so in the presence 
of hypertension and/or coronary heart disease.1–3 Epidemio-
logic studies showed that the presence of diabetes results Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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in increased cardiovascular mortality by nearly three-fold 
in men and five-fold in women,35 increased prevalence of 
coronary heart disease,36 increased risk of cardiovascular 
disease,37 and increased risk of renal disease and other mac-
rovascular and microvascular complications.1,38
Renin-angiotensin system inhibitors 
for hypertension  
and cardiovascular risk  
in the elderly
It is well recognized that the renin-angiotensin system plays 
a central role in regulation of blood pressure, fluid and elec-
trolyte balance, and the pathophysiology of cardiovascular 
disease (see Figure 1).4–8 Angiotensin II, the primary effector 
peptide of the renin-angiotensin system, not only increases 
blood pressure but also promotes vascular inflammation, 
leading to endothelial dysfunction and atherosclerosis, 
stimulates vascular smooth muscle hypertrophy, and 
vascular remodeling, and stimulates myocardial fibrosis 
and   hypertrophy, leading to cardiac remodeling.4–8 It also 
increases aldosterone, which stimulates fibrosis and cardio-
vascular remodeling (see Figure 1). Most of the effects of 
angiotensin II are mediated via AT1 receptors, providing a 
rationale for ACE inhibition and AT1 receptor blockade (see 
Figure 1). Importantly, aging is associated with increased 
angiotensin II and other renin-angiotensin system compo-
nents which, in turn, may contribute to increased cardiovas-
cular remodeling and cardiovascular risk in the elderly.23
ACE inhibitors for  
cardiovascular risk
Cumulative evidence suggests that renin-angiotensin system 
activation plays a critical role in increasing cardiovascular 
events, and renin-angiotensin system inhibition with ACE 
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Figure 1 Pathways of cardiovascular protection induced by ACe inhibition and ARBs.
Abbreviations: cGMP, cyclic guanosine 3′5′ monophosphate; eDHF, endothelin-derived hyperpolarizing factor; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; 
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inhibitors reduces cardiovascular risk.39 ACE inhibitors 
effectively control blood pressure in patients with hyperten-
sion, and have additional beneficial effects on cardiovas-
cular risk factors, including coronary heart disease, stroke, 
myocardial infarction, heart failure, diabetes, and chronic 
kidney disease. Randomized clinical trials have established 
that ACE inhibitors reduce rates of death, myocardial 
infarction, and stroke in patients with heart failure,40 left 
ventricular dysfunction,41 vascular disease,42–44 and high-
risk diabetes.3
Four trials specifically addressed whether ACE inhibi-
tors reduce cardiovascular events in low- to high-risk 
patients. First, the HOPE (Heart Outcomes Prevention 
Evaluation) study2 showed improvement in prognosis 
using the ACE inhibitor, ramipril, with a decreased rate of 
death, myocardial infarction, and stroke in a broad range of 
high-risk patients (including diabetes) for cardiovascular 
events and without low ejection fraction or heart failure. 
HOPE decreased new-onset diabetes and complications 
of diabetes. Second, EUROPA (European trial On reduc-
tion of cardiac events with Perindopril in stable coronary 
Artery disease),42 which included patients with coronary 
artery disease at lower risk than in HOPE and without 
left ventricular dysfunction, showed improvement in the 
composite endpoint of cardiovascular mortality, myocardial 
infarction, and resuscitation. Third, QUIET (QUinapril 
Ischemic Event Trial),43 which included low-risk patients, 
found no significant benefit. Fourth, the PEACE (Pre-
vention of Events with Angiotensin-Converting Enzyme 
inhibition) trial,44 which included low-risk patients and 
used the ACE inhibitor, trandolapril, found no significant 
benefit. However, the dose of the ACE inhibitors in QUIET 
and PEACE may have been suboptimal. Moreover, a meta-
analysis of these trials, with pooled data for 31,600 patients, 
showed that ACE inhibitors are effective in preventing 
cardiovascular events, with a 26% reduction in the risk of 
heart failure or stroke, and a 13%–18% reduction in total 
and cardiovascular mortality and myocardial infarction 
compared with placebo.45
Several studies suggested that ACE inhibitors not only 
reduce stroke by controlling blood pressure but may also 
prevent renal complications of diabetes.46 The HOPE/
TOO (The ongoing Outcomes) study found decreased 
development of diabetes in the follow-up phase, suggesting 
an added benefit of long-term ramipril.47 In the MICRO 
(MIcroalbuminuria Cardiovascular and Renal Outcomes) 
HOPE substudy,3 ramipril was beneficial for cardiovascular 
events and overt nephropathy in patients with diabetes. 
In the ADVANCE (Action in Diabetes and Vascular disease: 
preterAx and diamicroN-MR Controlled Evaluation) trial, 
the ACE inhibitor, perindopril, together with the diuretic, 
indapamide, reduced the risks of major vascular events and 
death in type 2 diabetes.48
AT 1 receptor blockers  
for cardiovascular risk
Because ACE inhibitors do not block angiotensin II gen-
erated in cardiovascular and other tissues via non-ACE 
pathways, the ability of ARBs to block angiotensin II at 
the AT1 receptor selectively, resulting in more complete 
inhibition, was considered advantageous (see Figure).49 
Unlike ARBs, ACE inhibitors increase bradykinin by 
suppressing its degradation, thereby enhancing vasodila-
tion, but also increasing cough and angioneurotic edema 
that are troublesome in approximately 20% of patients, 
especially in women and Asians.2,3,49 ARBs may result in 
unopposed angiotensin II type 2 (AT2) receptor activation 
and enhance vasodilation via downstream AT2-mediated 
signaling.49 Apart from blocking deleterious effects of 
angiotensin II and controlling blood pressure, ARBs might 
have protective effects similar to those of ACE inhibi-
tors. Data from randomized clinical trials showed that 
ARBs effectively control blood pressure in hypertension 
and are well tolerated.50 However, despite well known 
arguments for using ARBs, as reviewed previously,49 
whether ARBs are as effective as ACE inhibitors in 
reducing events such as stroke and myocardial infarction 
has been questioned.51 Moreover, ARBs can also release 
kinins and increase bradykinin levels in hypertensive 
patients,50,52 and thereby mediate cardiovascular protec-
tion.49 Such an ARB-induced increase in bradykinin can 
augment therapeutic actions, but can also lead to cough 
and angioedema.50,52 In the counterregulatory arm of the 
renin-angiotensin system, both ACE inhibitors and ARBs 
can increase angiotensin-(1–7).49
A complicating factor with the use of ACE inhibitors in 
heart failure patients is that angiotensin II levels increase 
and symptoms worsen.53 However, studies in hypertension 
have shown that ARBs, such as losartan and valsartan, are as 
effective as ACE inhibitors in lowering blood pressure.54,55 In 
hypertensive patients with ACE inhibitor-induced cough, this 
complication is less frequent with ARBs.56 In patients with 
heart failure and low ejection fraction, an ARB was shown to 
reduce the rate of death or hospitalization relative to placebo 
in those patients who could not tolerate an ACE inhibitor,57 
or were already receiving one.58,59 In the LIFE (Losartan Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Intervention For Endpoint reduction in hypertension) study, 
compared with beta-blockers, ARBs reduced vascular events 
in high-risk patients with hypertension and left ventricular 
hypertrophy.60 Taken together, these studies suggest that an 
ARB is an effective and well tolerated alternative to an ACE 
inhibitor for cardiovascular protection.
Because ACE inhibitors preceded ARBs for treating 
hypertension and heart failure, it has become necessary 
in clinical trials to demonstrate noninferiority or superior-
ity of an ARB over an ACE inhibitor as comparator. In 
patients with myocardial infarction, two studies comparing 
an ARB with an ACE inhibitor produced different results. 
OPTIMAAL (OPtimal Trial In Myocardial infarction with 
Angiotensin II Antagonist Losartan)61 and VALIANT (VAL-
sartan In Acute Myocardial Infarction Trial)62 compared the 
ARBs, losartan and valsartan, respectively, with the ACE 
inhibitor, captopril, in patients with signs of heart failure 
within 10 days of myocardial infarction. In OPTIMAAL, 
the ARB was not superior and the noninferiority criteria 
were not met; in fact, there was an increase in cardiovascular 
mortality after a 2.7-year mean follow-up.61 In VALIANT, 
the ARB was nonsuperior and noninferior for mortality and 
the composite endpoint of fatal and nonfatal events. The 
study established that valsartan was as effective as an ACE 
inhibitor in reducing mortality in high-risk survivors of 
myocardial infarction.62 A meta-analysis of 54,254 patients 
from 11 trials showed a potential 18% increase in myocar-
dial infarction with ARBs compared with placebo and a 
possible increase compared with other active therapy.63 In a 
separate meta-analysis of 55,050 patients from 11 trials that 
compared ARBs with either placebo or an active comparator, 
ARBs were found to reduce event rates for stroke, not to 
reduce event rates for global death, and to increase rates of 
myocardial infarction by 8%.51 The cloud of doubt cast by 
these reports has been partly dispelled by studies with the 
ARB telmisartan.15–18
Telmisartan for hypertension  
and cardiovascular risk
The AT1 antagonist telmisartan is an orally active, selective, 
biphenyl, nontetrazole, 6-substituted benzimidazole amino-
peptide that has no apparent AT1 agonist activity and does 
not interact with other receptors involved in cardiovascular 
regulation.9,64 Studies in various experimental models have 
shown that telmisartan is a more potent antihypertensive 
agent than losartan,9 and reduces glomerulosclerosis and 
cardiac hypertrophy.9 Telmisartan has a long half-life and 
sustained blood pressure-lowering activity. Studies in 
patients showed that a telmisartan 80 mg once daily dose was 
very effective in lowering diastolic blood pressure,65,66 with 
no difference in pharmacokinetics found between healthy 
elderly and younger subjects.19
Potential problems with treatment 
of hypertension in the elderly
Treatment of hypertension in elderly patients is more chal-
lenging than in the nonelderly because of aging-related 
biologic (Table 1) and pathophysiologic (Table 2) changes 
and associated comorbidities and polypharmacy. Common 
problems are listed in Table 3. Comorbidities, including obe-
sity, metabolic syndrome, and diabetes, not only aggravate 
the total cardiovascular disease burden but complicate man-
agement. Polypharmacy can lead to drug interactions.67,68 
Typically, elderly patients have multiple drugs prescribed. 
Patients aged $65 years usually use 2–6 prescription and 
1–4 nonprescription drugs on a regular basis.68 Addition of 
other drugs substantially increases the possibility of adverse 
effects. The potential for an adverse effect of any drug is 
estimated to increase by 6% when taken with one drug, by 
50% when taken with five different drugs, and by 100% 
when taken with eight or more medications.68 Age-related 
changes in the gastrointestinal tract, body content of fat 
and water, and liver and renal function, alter drug pharma-
cokinetics, including absorption, distribution, metabolism, 
and excretion in the elderly. In addition, elderly patients 
may have blunted responses to diuretics, ACE inhibitors, 
beta-blockers, and positive inotropes. They may show 
heightened sensitivity to renal dysfunction, impairment of 
sodium and water excretion, postural hypotension, aggra-
vation of hypotension to treatments (ie, ACE inhibitors, 
Table 3 Problems with pharmacologic therapy in the elderly
• ↑ Susceptibility to postural hypotension with treatments
• ↑ Aggravation of hypotension with treatments
• ↑ Impaired balance and proprioception with treatments
•   ↑ Susceptibility to sick sinus syndrome and bradyarrhythmias with 
treatments
• ↑ Adverse drug reactions and ↓ compliance
• ↑ Risk of drug interactions
•   Altered pharmacokinetics, impaired metabolism, and clearance of drug 
treatments
• ↑ Susceptibility to renal dysfunction with drug treatments
• ↑ Impaired sodium and water excretion with drug treatments
•   Altered response to diuretics, ACe inhibitors, ARBs, beta-blockers, 
positive inotropes
Notes: ↑, increase; ↓, decrease. 
Abbreviations: ACe, angiotensin converting enzyme; ARB, angiotensin II type 1 
(AT1) receptor blocker.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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beta-blockers, ARBs, nitrates, hydralazine, and diuretics) 
besides cognitive impairment and general frailty. Because 
of the physiologic changes that occur with aging, several 
precautionary measures are necessary with the pharmaco-
therapy of hypertension, myocardial infarction, and heart 
failure in the elderly.30,67 Also because of the age-related 
changes (Table 3) and impact of comorbidities, therapy 
needs to be individualized.
Telmisartan for hypertension  
in the elderly
Given its pharmacodynamic profile, telmisartan appeared 
well suited for treating hypertension in the elderly,19,69 but this 
needed testing. In a 26-week, multicenter study of 278 elderly 
patients (aged $65 years, mean age 71 years) with primary 
hypertension,19 Karlberg et al used a careful dose titration 
scheme, starting with 20 mg and escalating to 40 mg and 
80 mg of telmisartan based on the blood pressure response, 
and addition of hydrochlorothiazide if the 80 mg dose was not 
sufficient. Importantly, the dose of telmisartan was increased 
from 20 mg to 40–80 mg and enalapril from 5 mg to 10–20 mg 
at four-week intervals until the trough supine blood pressure 
was ,90 mmHg. Only after 12 weeks, hydrochlorothiazide 
12.5–25 mg once daily was added to the treatment regimen 
of patients who were not controlled on monotherapy.19 The 
study showed that both regimens provided effective lowering 
of blood pressure over the 24-hour dosing interval based on 
ambulatory blood pressure monitoring.
Although both regimens were well tolerated, the enalapril 
regimen was associated with more than double the incidence 
of treatment-related cough compared with the telmisartan 
regimen (16% versus 6.5%, respectively).19 The overall 
findings of that small study suggested that telmisartan is 
well tolerated and at least as effective as enalapril for treat-
ing elderly patients with mild to moderate hypertension.19 
However, that study did not address cardiovascular risk.
Telmisartan and partial  
PPARγ agonism
In addition to renin-angiotensin system inhibition, telmisartan 
acts as a selective partial agonist of PPARγ, an intracellular 
nuclear hormone receptor that is involved in the regulation of 
carbohydrate and lipid metabolism. Discovery of this unique 
property of telmisartan has attracted attention because of its 
therapeutic potential in elderly patients with obesity, metabolic 
syndrome, and type 2 diabetes. Several studies have shown that 
PPARγ plays an important role as a   regulator of carbohydrate 
and lipid metabolism,70,71 and ligands for PPARγ improve 
insulin sensitivity,72 reduce triglyceride levels,72 decrease risk 
of atherosclerosis,73 reduce vascular and cardiac effects of 
hypertension,74 and promote peripheral vasodilation.75–77
Although thiazolidinedione ligands for PPARγ were 
approved for the treatment of type 2 diabetes, these agents 
alone do not control blood pressure in hypertension and can 
provoke weight gain, edema, and heart failure in diabetics.78 
Despite reported beneficial effects of the thiazolidinediones, 
ie, pioglitazone and rosiglitazone, in animal models of 
ischemia-reperfusion injury and postinfarction ventricular 
remodeling,79–81 the finding that rosiglitazone increases mortal-
ity post myocardial infarction in rats82 led to grave concerns 
about the use of thiazolidinediones in diabetics. A teleoanalysis 
of clinical trials showed an increased risk of heart failure with 
both thiazolidinediones in patients with type 2 diabetes.14 More 
recently, patients treated with rosiglitazone showed an increased 
risk of myocardial infarction, stroke, heart failure, and death 
in high-risk elderly diabetics compared with pioglitazone.83 
These side effects may not be unique to the thiazolidinedione 
moiety because they can also occur with nonthiazolidinedione 
ligands.9 Thiazolidinedione-induced fluid retention and heart 
failure appears to be related not to left ventricular dysfunction,9 
but rather to increased sodium reabsorption mediated by the 
renal PPARγ pathway in collecting tubules.84 Moreover, both 
thiazolidinediones are under review by the US Food and Drug 
Administration, and restrictions have been applied with the use 
of rosiglitazone. The 2010 consensus is that thiazolidinediones 
should be avoided in older patients with type 2 diabetes and 
class III/IV heart failure and should not be used for reducing 
cardiovascular events.
Elegant molecular modeling studies by Benson et al9 
established two important points. First, telmisartan is only a 
partial PPARγ agonist and might influence PPARγ activity 
by interacting with regions of the ligand-binding domain that 
are not typically engaged by full PPARγ agonists. Second, 
other ARBs lack the potential of telmisartan for receptor 
interaction and have little or no PPARγ activity. Given that 
renin-angiotensin system blockade with telmisartan can 
inhibit renal sodium reabsorption and attenuate fluid reten-
tion and edema, the potential heart failure complication seen 
with thiazolidinediones should not be a source of concern 
with the use of telmisartan in diabetics.9
Several other clinical and experimental studies support 
the beneficial effect of telmisartan via PPARγ activity. First, 
a small comparative study of telmisartan 40–80 mg and enal-
april 10–20 mg in 250 patients with hypertension and early 
type 2 diabetic nephropathy (age .40 years) showed that, 
over the five-year study period, telmisartan is   noninferior Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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to enalapril in conferring renoprotection.88 Second, another 
small comparative study of telmisartan 80 mg and losartan 
50 mg for three months in 40 patients, mean age 55–56 years, 
with hypertension and metabolic syndrome, showed that 
telmisartan provides superior control of blood pressure and 
displays insulin-sensitizing activity consistent with its partial 
PPARγ activity.10 Third, telmisartan (but not eprosartan) was 
shown to increase nitric oxide synthesis sufficient to delay 
aging of human umbilical vein endothelial cells via activa-
tion of PPARγ signaling.11 Fourth, telmisartan was shown 
to attenuate fatty acid-induced oxidative stress in mouse 
pancreatic β-cells, suggesting that it may preserve insulin 
secretion capacity in diabetics.12 Fifth, a recent small study 
of 39 patients with essential hypertension (mean age 61 ± 
6 years) showed that telmisartan 80 mg daily effectively 
improved vascular endothelial function and arterial stiff-
ness after eight weeks, consistent with increased PPARγ 
activity.13
The collective evidence suggests that, among the anti-
hypertensive drugs that inhibit the renin-angiotensin sys-
tem, telmisartan is safe and effective for elderly patients.19 
Whether its partial PPARγ agonism might be an added 
advantage for high-risk elderly patients needs further evalu-
ation in larger clinical trials. Pending the results, caution 
might be prudent.
Do other renin-angiotensin system 
inhibitors have PPARγ activity?
Among other ARBs, only irbesartan was found to have 
significant PPARγ agonist activity, but that was modest 
compared with telmisartan.9 A subsequent prospective 
observational study in 3259 patients with hypertension 
and metabolic syndrome or diabetes showed improve-
ment in metabolic parameters with irbesartan 150 mg or 
300 mg daily with or without hydrochlorothiazide 12.5 mg 
daily after six months.85 Importantly, these changes were 
more pronounced in male and obese patients.85 How-
ever, the mean age of the patients in that study was only 
61.5 ± 10.5 years.85 The renal benefits of ARBs in patients 
with type 2 diabetes as previously reported with losartan 
(albeit in patients aged 60 ± 7 years),86 were most likely 
due to blockade of the effects of angiotensin II through the 
AT1 receptor,86 and possibly by enhancing effects through 
the AT2 receptor.87 The extensively reported beneficial 
effects of ACE inhibitors in type 2 diabetes47,48 are most 
likely due to the combined effects of increased bradykinin 
and decreased angiotensin II via AT1 and AT2 receptors 
rather than PPARγ.9
ONTARGET study
The ONTARGET investigators compared telmisartan (80 mg 
daily, n = 8542) with the ACE inhibitor, enalapril 10 mg daily 
(n = 8576) as the comparator or combined with ramipril as 
background therapy (n = 8502) in patients with vascular 
disease or high-risk diabetes over a median of 56 months.15 
Patients aged $55 years were enrolled. Mean ages were 
66.4 ± 7.2, 66.4 ± 7.1 and 66.5 ± 7.3 years, respectively. Mean 
baseline blood pressures averaged 142 ± 17/82 ± 10 mmHg 
in the three groups. Telmisartan was noninferior to or as 
effective as ramipril for prevention of the composite primary 
outcome (cardiovascular deaths, myocardial infarction, or 
heart failure hospitalization) as well as individual compo-
nents of the outcome. However, blood pressure reduction was 
greater with telmisartan and combination therapy compared 
with enalapril monotherapy. Also, compared with enalapril 
monotherapy, telmisartan monotherapy was associated with 
less cough (1.1% versus 4.2%) and angioedema (0.1% versus 
0.3%) and more hypotensive symptoms (2.6% versus 1.7%) 
and similar rates of syncope (0.2%). Compared with either 
monotherapy, combination therapy was associated with 
more adverse events (hypotensive symptoms, 4.8% versus 
1.7%; syncope, 0.3% versus 0.2%; renal impairment, 13.5% 
versus 10.2%; hyperkalemia [.5.5 mmol/L]: combination 
therapy [480 patients] versus telmisartan [287 patients] 
versus ramipril [283 patients], P , 0.001) and without 
increased benefits.
Five points in ONTARGET deserve emphasis. First, 
although the population was similar to that in HOPE,2 
adherence to the ACE inhibitor, ramipril, was higher than 
in HOPE.15 Second, the discontinuation rate was lower and 
compliance higher with telmisartan than with ramipril.15 In 
previous randomized clinical trials, 20% of patients were 
unable to tolerate ACE inhibitors.2,3,45 Third, although the 
population was quite different from that in VALIANT 
which selected those with left ventricular dysfunction and 
postinfarction heart failure, VALIANT also showed non-
inferiority to an ACE inhibitor (ie, captopril).62 Fourth, as 
in VALIANT,62 a greater decrease in blood pressure with 
combination therapy was not associated with greater benefits, 
likely because of the offsetting effect of increased risk of 
hypotension, syncope, renal dysfunction, and hyperkalemia. 
In addition, the potential benefits of dual renin-angiotensin 
system inhibition may have been blunted by combination 
with beta-blockers, which were used in approximately 55% 
of patients. A similar interaction was noted in VALHeFT 
(the VALsartan HEart Failure Trial).58 Fifth, in contrast 
with CHARM (Candesartan in Heart Failure – Assessment Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
411
Telmisartan for hypertension in the elderly
of Mortality and Morbidity),59 which enrolled heart failure 
patients and added the ARB candesartan to an ACE inhibitor 
in variable doses (,50% on full doses), and VALHeFT,58 
which enrolled heart failure patients and compared valsartan 
with a placebo group of which 90% received background 
ACE inhibitors in submaximal doses, combination therapy 
was superior to placebo.
Taken together, the ONTARGET data suggest that there 
is no added advantage of combination therapy at full doses 
in older adult and younger elderly patients. Careful titra-
tion should be the rule when combining ARBs with ACE 
inhibitors, both of which are powerful vasodilators, to avoid 
hypotension, especially in elderly and very old patients. The 
dose regimen used by Karlberg et al was cautious, wise, and 
effective.19 The harmful paradoxical J-curve or U-curve 
effect of decreased blood pressure and hypoperfusion with 
vasodilator therapy was demonstrated for acute myocardial 
infarction, both in experimental and clinical settings.89–93 This 
is likely true for hypertension,94 especially in elderly patients 
with physiologic increases in cardiac and vascular stiffness 
(Table 2), although definitive confirmation in appropriate 
randomized clinical trials of more elderly patient popula-
tions is needed.6
TRANSCEND study
By design, TRANSCEND17 compared telmisartan 80 mg 
once daily (n = 2954) with placebo (n = 2972) in patients 
intolerant to ACE inhibitors and with cardiovascular disease 
or diabetes with end-organ damage over a median duration 
of 56 months. The patients were identified after a three-week 
run-in period. Mean age was 66.9 years, and baseline blood 
pressure averaged 141/82 mmHg for both groups. Their 
study population included patients selected from ONTAR-
GET because of ACE inhibitor intolerance. Telmisartan was 
well tolerated, but did not affect the ONTARGET primary 
outcome (composite of cardiovascular death, myocardial 
infarction, stroke, or hospitalization for heart failure). How-
ever, telmisartan modestly reduced the secondary outcome 
(composite of cardiovascular death, myocardial infarction, or 
stroke) compared with placebo (13.0% versus 14.8%; unad-
justed P = 0.048 and adjusted P = 0.068). Discontinuation 
was less with telmisartan than placebo (21.6% versus 23.8%; 
P = 0.055) and this was mostly for hypotension (0.098% 
versus 0.54%; P = 0.049); rates of syncope (1% versus 0%), 
cough (0.51% versus 0.61%), angioedema (0.07% versus 
0.10%), and renal dysfunction (0.81% versus 0.44%) were 
low and not different between the groups. Telmisartan had 
no effect on rates of hospitalization for heart failure, at least 
initially in the first six months but showed clear benefit after 
six months.
Five points in TRANSCEND deserve comment. First, the 
finding that telmisartan did not reduce the primary composite 
outcome but reduced the secondary composite outcome that 
excluded heart failure should be interpreted with caution. The 
population was especially selected to exclude not only ACE-
intolerant patients but also patients with heart failure, and few 
had left ventricular hypertrophy. Selection may have excluded 
patients at higher risk and those likely to show benefit for 
heart failure. Hospitalization for heart failure was low for 
telmisartan and placebo (4.5% versus 4.3%), and any heart 
failure event was also low (6.5% versus 6.6%). Although 
many previous randomized clinical trials established that 
ACE inhibitors42,45 and ARBs56,59,61,95 reduce heart failure hos-
pitalization, the patients in those studies were at higher risk 
for heart failure or left ventricular hypertrophy. Other stud-
ies with ACE inhibitors48,96 and ARBs97 in low-risk patients 
did not show a decrease in heart failure hospitalization.48,96 
In ONTARGET, heart failure hospitalization rates were 
similar for telmisartan and ramipril (4.6% versus 4.1%). 
In TRANSCEND, rates of myocardial infarction were also 
lower than in HOPE (1.09% versus 3.06% per year). Thus, 
the TRANSCEND population was altogether a lower risk 
group for heart failure.
Second, the authors suggest that a similar lack of benefit 
in the primary composite outcome as in TRANSCEND was 
found in the ProFESS (Prevention Regimen for Effectively 
Avoiding Second Strokes) study comparing telmisartan with 
placebo over 2.5 years in patients with recent stroke.16,17,97 
They show, in a prespecified analysis of the combined data of 
the two trials, a reduction in the primary composite outcome 
after six months (9.3 versus 10.8%; P , 0.001) but not before 
six months (3.8% versus 3.4%; P = 0.074).17 This finding 
suggests that prolonged therapy is needed for the heart failure 
benefit to manifest in that low-risk population.
Third, because HOPE preceded ONTARGET and 
TRANSCEND by over five years, this may have influenced 
background therapies in both the treatment and placebo 
groups. Thus, statin use was higher in TRANSCEND than 
in previous trials.17 Higher diuretic and beta-blocker use may 
have impacted on heart failure, and higher antiplatelet use 
may have impacted on stroke.
Fourth, even in the population with low heart failure risk 
in TRANSCEND, the rate of myocardial infarction was lower 
with telmisartan versus placebo (3.9% versus 5.0%; P = 0.059) 
and similar to that with the ACE inhibitor in ONTARGET 
(4.8% versus 5.2%),15 suggesting that the previously voiced Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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concern with ARB use51,98 did not apply in these patients. The 
lower rate of stroke in TRANSCEND was not statistically 
significant (3.8% versus 4.6%; P = 0.136) but the secondary 
composite outcome, including stroke, was significantly lower 
(13.0% versus 14.8%; P = 0.048). This beneficial effect of 
an ARB on cerebrovascular events is consistent with other 
reports.15,59 Fifth, an important finding is that even patients 
who experienced angioneurotic edema and other adverse 
effects on ACE inhibitors tolerated telmisartan.
Telmisartan and risk of stroke  
in ProFESS
Previous studies showed that ACE inhibitors and ARBs after 
remote stroke are beneficial. PROGRESS (the Perindopril 
Protection against Recurrent Stroke Study) showed lowering 
of blood pressure in patients with substantial elevation using 
an ACE inhibitor and diuretic reduced the risk of recur-
rent stroke.99 HOPE showed that an ACE inhibitor reduces 
the rate of stroke in patients with previous cardiovascular 
events or high-risk diabetes despite mild lowering of blood 
pressure.3 The ARB, eprosartan, reduced recurrent stroke 
compared with a calcium channel blocker despite similar 
blood pressure reduction.100 The ARB, candesartan, given 
early after a stroke reduced rates of death despite no blood 
pressure reduction.101
The ProFESS study16 compared telmisartan 80 mg daily 
(n = 10,146) with placebo (n = 10,186) initiated early after 
an ischemic stroke, less than 90 days before randomization. 
Patients were aged 50 years or older, and mean ages were sim-
ilar (telmisartan 66.1 ± 8.6 years, placebo 66.2 ± 8.6 years). 
The mean interval from stroke was 15 days. Baseline mean 
blood pressure averaged 144.1/83.8 mmHg for the two 
groups. The mean follow-up was 2.5 years. The data showed 
that telmisartan did not significantly lower the rate of recur-
rent stroke (8.7% versus 9.2%; P = 0.23), major cardiovas-
cular events (13.5% versus 14.4%; P = 0.11), or new-onset 
diabetes (1.7% versus 2.1%; P = 0.10). The reasons for the 
lack of benefit of telmisartan in that study are not clear. As 
suggested by the authors, the effect of telmisartan may be 
time-dependent because the 2.5 years was shorter compared 
with HOPE (4.5 years) and PROGRESS (4.0 years) which 
showed benefit. The lack of effect on new-onset diabetes is 
not consistent with previous studies that showed reduced risk 
of diabetes with ACE inhibitors and ARBs.102,103 In addition, 
the PPARγ activity of telmisartan should have resulted in 
benefit. However, the only large trial with diabetes as the pri-
mary outcome did not find significant benefit with ramipril,96 
suggesting that other factors may be involved.
The ProFESS trial also compared the efficacy of prophy-
lactic treatment using aspirin 25 mg daily plus extended-
release dipyridamole 200 mg twice daily (n = 10,181) versus 
clopidogrel 75 mg daily (n = 10,151) and either telmisartan 
80 mg daily (n = 10,146) or placebo (n = 10,186) on reduction 
of disability and recurrent strokes97 in patients with ischemic 
stroke. In this study too, the data did not show improvement 
in functional or cognitive outcome comparing the two anti-
platelet treatments or telmisartan versus placebo.97
Telmisartan and left  
ventricular hypertrophy
ONTARGET and TRANSCEND also provided important 
new data on the effect of telmisartan on left ventricular 
hypertrophy in high-risk patients without heart failure.15 
At entry, the prevalence of left ventricular hypertrophy 
based on electrocardiograms in the two cohorts was 12.4% 
and 12.7%, respectively. Mean age was 66–67 years. In 
the ACE inhibitor-intolerant patients of TRANSCEND, 
telmisartan reduced the prevalence of left ventricular 
hypertrophy (P = 0.0017) compared with placebo at two 
years (10.5% versus 12.7%) and five years (9.9% versus 
12.8%). Importantly, telmisartan suppressed new-onset left 
ventricular hypertrophy (P = 0.0001) although left ventricular 
hypertrophy regression was similar. In the ACE inhibitor-
tolerant patients of ONTARGET, left ventricular hypertrophy 
prevalence was lower with both telmisartan (P = 0.07) and 
the combination (P = 0.12) compared with ramipril alone, 
although the differences were not significant. Interestingly, 
new onset left ventricular hypertrophy was associated with a 
higher risk of the primary outcome during follow-up. Taken 
together, telmisartan was more effective than placebo in 
reducing left ventricular hypertrophy, and new onset left 
ventricular hypertrophy was reduced by 37%. However, 
combination of telmisartan with ramipril was not superior 
to ramipril alone.
Eight points deserve mention. First, the placebo group 
received intensive therapy but no renin-angiotensin system-
blocking drugs. Second, the telmisartan-induced decrease in 
left ventricular hypertrophy over placebo in TRANSCEND 
did not translate into decrease in heart failure, and the 
telmisartan-induced greater decrease in left ventricular hyper-
trophy over ramipril in ONTARGET did not affect outcome. 
Third, the lack of difference in left ventricular hypertrophy 
regression despite a significant decrease in new-onset left 
ventricular hypertrophy with telmisartan versus placebo in 
TRANSCEND may be due to the modest decrease in blood 
pressure with telmisartan. Fourth, the prognostic value of Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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left ventricular hypertrophy regression may be reduced in 
hypertensive patients with left ventricular hypertrophy and 
diabetes compared with those with left ventricular hyper-
trophy but no diabetes. Fifth, it was unclear why the lower 
prevalence of left ventricular hypertrophy with telmisartan 
versus ramipril was not statistically significant when other 
studies showed comparable left ventricular hypertrophy 
regression with ACE inhibitors and ARBs.104 Due to cost, the 
study used electrocardiographic criteria for left ventricular 
hypertrophy rather than echocardiographic left ventricular 
mass. However, a substudy of 297 ONTARGET patients 
using magnetic resonance imaging at baseline and at two 
years showed no left ventricular hypertrophy in the majority 
at baseline, but a similar decrease in left ventricular mass in 
all three groups.105
Sixth, when left ventricular hypertrophy is present at 
baseline, greater left ventricular hypertrophy regression with 
an ARB than an ACE inhibitor may result from enhanced AT2 
receptor activation during AT1 receptor blockade.44 This effect 
may be further amplified in hypertrophic hearts that have AT2 
receptor upregulation, which leads to increased antiprolifera-
tive and antifibrotic effects (see Figure 1) that oppose AT1 
receptor stimulation of hypertrophy and remodeling.
Seventh, the reason why combination therapy showed 
statistically nonsignificant lower left ventricular hypertrophy 
prevalence than with ramipril alone is unclear. It is pos-
sible that a decline in renal function with combined renin-
angiotensin system inhibition blunted the decrease in left 
ventricular hypertrophy.106 It is also possible that decreased 
angiotensin II stimulation of AT2 receptors during ACE 
inhibition limited the decrease in left ventricular hypertrophy. 
Eighth, the finding of increased risk of the primary outcome 
with left ventricular hypertrophy is consistent with HOPE, 
which showed that left ventricular hypertrophy by electro-
cardiographic voltage criteria was an independent predictor 
of outcome in high-risk patients. In addition, subendocardial 
ischemia associated with concentric left ventricular hyper-
trophy in the presence or absence of coronary disease, may 
also increase risk.
Meta-analysis of randomized  
clinical trials on telmisartan  
in hypertension
A recent meta-analysis of randomized clinical trials of telm-
isartan versus ACE inhibitors for patients with hypertension 
(mean age 40–75 years) showed that telmisartan provides 
superior blood pressure control, with fewer adverse effects 
and better tolerability.107
Conclusion
The totality of the evidence from the two comparative megatri-
als, ONTARGET and TRANSCEND, and other studies suggest 
that the ARB, telmisartan, produces benefits beyond blood 
pressure reduction in older adult and younger elderly patients 
with vascular disease or high-risk diabetes that equal those of 
the ACE inhibitor, ramipril. Because telmisartan is equally 
effective and better tolerated than ramipril, this is an advantage 
for compliance in elderly patients. Thus, telmisartan appears to 
be an attractive alternative to an ACE inhibitor or a preferred 
ARB in ACE-intolerant patients. The finding of a greater blood 
pressure reduction with telmisartan suggests the need for careful 
dose titration and blood pressure monitoring in high-risk elderly 
patients, especially in view of age-related changes. The only 
small trial of telmisartan in elderly patients used careful dose 
titration and blood pressure monitoring, and showed effective 
blood pressure control. The possibility that the partial PPARγ 
activity of telmisartan might confer added benefits in high-
risk elderly patients with diabetes is potentially important and 
needs clinical verification. The finding of increased adverse 
effects without added benefit with the combination of full-dose 
telmisartan and ramipril suggests that ARB–ACE inhibitor 
combinations should be either avoided or used with extreme 
caution in high-risk elderly patients. The potential importance 
of additional benefits of telmisartan beyond renin-angiotensin 
system inhibition on cardiovascular risk and new-onset diabe-
tes deserves further study in carefully designed randomized 
clinical trials in elderly patients aged .65 years, .75 years, 
and .85 years, as well as nonelderly subjects.
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